BrainVectis

18 route du Panorama
Fontenay-aux-Roses
92260
France

Show jobs for this employer

About BrainVectis

BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Dr. Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is currently focusing on Huntington's disease and Alzheimer's disease, two serious and irreversible diseases for which as yet no effective treatment exists. BrainVectis is based in Fontenay aux Roses and has five employees. The company raised €1 million ($1.1m) in September 2016 in a series A round of financing.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder and CEO: Jerome Becquart, PhD
Founder and CSO: Nathalie Cartier-Lacave, MD

2 articles about BrainVectis